Navigation Links
Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism
Date:2/3/2010

VT, non-fatal PE and fatal PE). The primary safety assessment of the trial is the incidence of major and clinically relevant non-major bleeding.

"HOKUSAI VTE is the largest, single Phase III study ever undertaken in the area of VTE, and is our second large-scale edoxaban trial," said Glenn Gormley, president of Daiichi Sankyo Pharma Development. "Daiichi Sankyo is proud to be advancing the research of Factor Xa inhibitors with edoxaban, which may help prevent deadly clots in various patient populations."  

HOKUSAI VTE Study Design

HOKUSAI VTE is a Phase III multi-center study that will include approximately 7,500 patients in more than 450 clinical sites in approximately 40 countries worldwide. This is an event-driven, randomized, double-blind, double-dummy, parallel-group, multi-center, multi-national study, which will randomize patients to two different treatment groups. Both groups will receive open label enoxaparin or unfractionated heparin for at least five days and up to 12 days, followed by double-blind warfarin or edoxaban 60 mg once-daily. Patients will be treated for up to 12 months in accordance to the standard of care and international guidelines.

The HOKUSAI VTE study is named after the famous Japanese artist and painter Katsushika Hokusai (1760-1849) of the former Edo period; Edo is the city currently known as Tokyo, the location of the Daiichi Sankyo global headquarters.  

About Venous Thromboembolism

Venous thromboembolism (VTE) is the term for the generation of a blood clot and the obstruction of a vein or a pulmonary artery by a blood clot. Deep vein thrombosis (DVT) and pulmonary embolism (PE) are types of VTE. DVT is a blood clot anywhere in the deep veins of the legs or pelvis. PE is caused by a clot that travels to the lungs, lodging in the pulmonary arteries.

Ab
'/>"/>

SOURCE Daiichi Sankyo
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation
2. Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application
3. Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b
4. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
5. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
8. Celsis Initiates Patent Infringement Action Against XenoTech and Sekisui
9. Romark Initiates Clinical Trial of Alinia for Treatment of Influenza
10. Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
11. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015  Vanda Pharmaceuticals Inc. ... top-line results of the Phase II proof of ... of tradipitant as a monotherapy in the treatment ... Despite a highly significant and clinically meaningful improvement ... p<0.0001) as measured on a 100mm unit Visual ...
(Date:3/4/2015)... -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" ... company in China, today announced its financial results for ... Fourth Quarter 2014 Financial Highlights , ... by 36.2%, or 36.8% excluding the impact of foreign ... million in the same quarter of 2013. , ...
(Date:3/4/2015)... GSI Group Inc. (NASDAQ: GSIG ... and supplier of precision photonics and motion control components ... technology markets, today reported financial results for the fourth ... financial results in this press release are GAAP measures ... fourth quarter of 2014, GSI generated revenue of $94.0 ...
Breaking Medicine Technology:Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 2Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 3Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 4Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 5Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 6Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 7China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 2China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 3China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 4China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 5China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 6China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 7China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 8China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 9China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 10China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 11China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 12China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 13China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 14China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 15China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 16China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 17China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 18China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 19China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 20China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 21China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 22GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 2GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 3GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 4GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 5GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 6GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 7GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 8GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 9
... Amgen (Nasdaq: AMGN ) will participate in ... the Four Seasons in Boston, beginning at 10:00 a.m. Eastern ... and Arvind Sood, vice president, Investor Relations will present at ... from the Events Calendar on Amgen,s website, www.amgen.com , ...
... YORK, Dec. 8, 2010 Reportlinker.com announces that a ... Europe Orthopedic Devices Market Outlook to ... Europe Orthopedic Devices Market Outlook to 2016 ... Orthopedic Devices Market Outlook to 2016" provides key market ...
Cached Medicine Technology:Reportlinker adds Europe Orthopedic Devices Market Outlook to 2016 2Reportlinker adds Europe Orthopedic Devices Market Outlook to 2016 3Reportlinker adds Europe Orthopedic Devices Market Outlook to 2016 4Reportlinker adds Europe Orthopedic Devices Market Outlook to 2016 5Reportlinker adds Europe Orthopedic Devices Market Outlook to 2016 6Reportlinker adds Europe Orthopedic Devices Market Outlook to 2016 7Reportlinker adds Europe Orthopedic Devices Market Outlook to 2016 8Reportlinker adds Europe Orthopedic Devices Market Outlook to 2016 9Reportlinker adds Europe Orthopedic Devices Market Outlook to 2016 10Reportlinker adds Europe Orthopedic Devices Market Outlook to 2016 11Reportlinker adds Europe Orthopedic Devices Market Outlook to 2016 12Reportlinker adds Europe Orthopedic Devices Market Outlook to 2016 13Reportlinker adds Europe Orthopedic Devices Market Outlook to 2016 14Reportlinker adds Europe Orthopedic Devices Market Outlook to 2016 15Reportlinker adds Europe Orthopedic Devices Market Outlook to 2016 16Reportlinker adds Europe Orthopedic Devices Market Outlook to 2016 17Reportlinker adds Europe Orthopedic Devices Market Outlook to 2016 18Reportlinker adds Europe Orthopedic Devices Market Outlook to 2016 19Reportlinker adds Europe Orthopedic Devices Market Outlook to 2016 20
(Date:3/5/2015)... 2015 Dr. Jonathan Glashow a board ... has been named by Castle Connolly as ... Dr. Glashow has been selected by Castle Connolly Medical ... top specialty care doctors in the tri-state metropolitan New ... program, which carefully screens and selects doctors through a ...
(Date:3/5/2015)... Today, Earth Source Organics (ESO) ... pollution-free electricity through a partnership with national Clean ... Arcadia Power Clean Energy Partner, ESO now meets ... requirements, joining national brands such as Whole Foods, ... Earth Source Organics joins a growing community of ...
(Date:3/5/2015)... 2015 Think it’s tough to get kids ... get them to brush their teeth. That’s a finding from ... by Delta Dental(1) in conjunction with National Parenting Month in ... getting kids to brush their teeth is one of the ... slightly higher than getting children to eat vegetables regularly (42 ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Altec Products, ... solutions, announced today their participation in the Houston, TX ... 2015. The Inspire Tour will unite Sage enterprise resource ... ideas about workable solutions to real-world business challenges. ... the Crowne Plaza Houston Galleria Area on March 10th. ...
(Date:3/5/2015)... 2015 T.E.N., a technology and ... finalists and winners Thursday evening, March 4, at ... Gala at the Westin Buckhead in Atlanta, GA. ... EarthLink, was selected as the Information Security Executive® ... Southeast Region. Pete is an industry veteran with ...
Breaking Medicine News(10 mins):Health News:Dr. Jonathan Glashow, NYC Orthopedic Surgeon, Named Top Doctor: New York Metro Area 2Health News:Earth Source Organics to Run on Clean Energy from Arcadia Power 2Health News:Delta Dental Survey Says Parents Have Harder Time Getting Kids to Brush than to Eat Vegetables 2Health News:Delta Dental Survey Says Parents Have Harder Time Getting Kids to Brush than to Eat Vegetables 3Health News:Altec Attends Sage Inspire Tour Stops in Houston and Charlotte to Showcase Sage ERP Document Management and Workflow Solution 2Health News:Altec Attends Sage Inspire Tour Stops in Houston and Charlotte to Showcase Sage ERP Document Management and Workflow Solution 3Health News:Pete Chronis of EarthLink and Jabil Claim Top Awards at ISE® Southeast 2Health News:Pete Chronis of EarthLink and Jabil Claim Top Awards at ISE® Southeast 3Health News:Pete Chronis of EarthLink and Jabil Claim Top Awards at ISE® Southeast 4
... hepatitis B-related liver damage should receive lifelong antiviral treatment ... study shows that they lack cellular immunity against the ... These findings are in the March issue of ... & Sons. The article is also available online at ...
... article appearing in the March 2009 issue of the ... may lead to improvements in the efficacy of the ... discovered a new role for type I interferon, in ... stimulate an immune response against the bacterium known to ...
... 26 A large new study provides evidence ... women from Parkinson,s disease. The study was released today and ... Annual Meeting in Seattle, April 25 to May 2, 2009.The ... lifespan (number of years from first menstruation to menopause) had ...
... decision issued by the U.S. District Court for the ... for the insurance industry. The February 13 ruling from ... the court entered two months earlier establishing that Texas ... policies to advance defense costs incurred in connection with ...
... and radiation used to save cancer patients, lives can ... new field called oncofertility has advanced the ability of ... and children who are diagnosed with cancer. Yet, many ... their patients. , A leading oncofertility researcher and a ...
... Most people accustomed to working within a managed care or ... care or the cost of that care. Often they ... they get the bill.But as healthcare costs skyrocket and layoffs ... (HDHP) with health savings accounts (HSA) are growing in popularity. ...
Cached Medicine News:Health News:Liver transplant recipients with hepatitis B may need lifelong antiviral treatment 2Health News:New discovery gives tuberculosis vaccine a shot in the arm 2Health News:Reproductive Factors May Protect Women from Parkinson's Disease 2Health News:Reproductive Factors May Protect Women from Parkinson's Disease 3Health News:Patton Boggs Wins Landmark Insurance Case for Client 2Health News:New tool guides doctors to save cancer patients' fertility 2Health News:New tool guides doctors to save cancer patients' fertility 3Health News:Five Steps to Improve Care and Lower the Cost of Your Surgery 2Health News:Five Steps to Improve Care and Lower the Cost of Your Surgery 3Health News:Five Steps to Improve Care and Lower the Cost of Your Surgery 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: